Healthcare Equities

The companies that provide, support or coordinate medical goods and services. This sector spans a broad range of activities – including the development and manufacture of medical equipment, pharmaceuticals and other treatments. Activities range from research to manufacturing, administration, insurance and facilities management. Our Healthcare research includes healthcare services, healthcare information technology (IT), medical devices, biotechnology, biopharmaceuticals and specialty pharmaceuticals.

Racura Oncology (ASX: RAC) advances RC220 trials with A$30.7m cash >

Arron Aatkar, PhD | Healthcare | Comment | 11 hours ago

Newron Pharmaceuticals (SIX: NWRN): Evenamide Phase III enrolment complete >

Arron Aatkar, PhD | Healthcare | Comment | 14 hours ago

BioVersys (SIX: BIOV): Peer-reviewed data support BV100 profile >

Jyoti Prakash, CFA | Healthcare | Comment | 3 days ago

Percheron Therapeutics (ASX: PER) expands HMBD-002’s development optionality >

Jyoti Prakash, CFA | Healthcare | Comment | 3 days ago

SEE ALL COMMENTARY >

Elicera Therapeutics (ELIC)

Latest price

SEK2.89

▾ 0.03 (0.87)

As at 21/10/2026

Market capitalisation: SEK193m

Equities

Equities by Sector

Sectors

Megatrends

Thematics

Latest

Edison explains: Moroccan copper – Competing for scarce development capital

The annual report has lost its way – can digital reforms be the fix it needs?

Edison explains: Petflation

Audiovisual

Latest

Bull, Bear & Beyond – Baillie Gifford US Growth Trust in 60 Seconds

Baillie Gifford US Growth Trust in 60 Seconds

Bull, Bear & Beyond – Planet2050: executive interview

About Edison

Corporates

Investors

Careers

Healthcare Equities

Elicera Therapeutics (ELIC)

SEK2.89

Elicera Therapeutics — Positioned to deliver in cell and gene therapies

See morecontent on

Ernexa Therapeutics (ERNA)

USD2.11

Ernexa Therapeutics — On the path to the clinic

See morecontent on

ExpreS2ion Biotech (EXPRS2)

SEK1.06

ExpreS2ion Biotech — Building the clinical data package

See morecontent on

Genedrive (GDR)

GBP0.01

Genedrive — Point-of-care diagnostics driving rapid care decisions

See morecontent on

Herantis Pharma (HRTIS)

EUR1.25

Herantis Pharma — H126 results reflect Phase II preparations

Herantis Pharma — FDA feedback clears HER-096 Phase IIa path

Herantis Pharma – equity proposition

See morecontent on

Hyloris Pharmaceuticals (HYL)

EUR3.90

Immix Biopharma (IMMX)

USD8.51

Immix Biopharma — NXC-201 data enhance the investment case

Immix Biopharma — Q226: funded to execute its CAR-T strategy

Immix Biopharma – equity proposition

See morecontent on

Kooth (KOO)

GBP1.83

Kooth – executive interview

Kooth — Improved profitability and growth drivers

Kooth — Soluna embeds as renewal risk recedes

See morecontent on

LTR Pharma (LTP)

AUD0.48

LTR Pharma — Sizable upside potential for intranasal delivery

See morecontent on

Mendus (IMMU)

SEK5.19

Mendus — AML durability and CML progress

Mendus — DIVA starts; testing combination with Ven+Aza

Mendus — Second Fenja drawdown extends runway

See morecontent on

MindMaze Therapeutics (MMTX)

CHF0.15

MindMaze Therapeutics — Progress on the neurotherapeutics roll-out

MindMaze Therapeutics — Organisational simplification supports way forward

MindMaze Therapeutics – equity proposition

See morecontent on

Newron Pharmaceuticals (NWRN)

CHF8.50

Newron Pharmaceuticals — Pivotal enrolment complete; FDA review continues

Newron Pharmaceuticals — H126 results: Evenamide pivotal readout nears

Newron Pharmaceuticals — Strengthened funding ahead of pivotal readout

See morecontent on

Ocugen (OCGN)

USD0.82

Ocugen — Novel cell therapies for retinal diseases

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on